About Chiesi

Chiesi is a research oriented biopharmaceutical group developing innovative therapies in respiratory health, rare diseases, and specialty care. The company focuses on Air for respiratory conditions like asthma and COPD, Rare for lysosomal storage disorders, and Care for neonatology. Operating across 100 nations with over 30 affiliates, Chiesi combines scientific rigour with environmental responsibility. As a certified B Corp, Chiesi works toward Net Zero emissions by 2035 while advancing Carbon Minimal Inhalers to lower the carbon footprint of respiratory treatments. With 90 years of experience, the company serves patients worldwide through evidence based medicines and transparent clinical data sharing.